🍬 Insulin vs Metformin Treatment Escalation Simulator

Diet and Exercise Failure Trigger

Lifestyle-only management stops working once fasting glucose stays elevated.

• ≥95: Fasting threshold (mg/dL typical trigger)
• ~15–30%: Failure rate (of GDM on lifestyle alone)
• 1–2 wks: Reassessment (glucose log review)
• Meds: Next step (oral or injectable)

When lifestyle control is declared insufficient

Placeholder: repeated above-target readings prompt escalation review.

Metformin Oral Therapy Option

Metformin is a common oral first-line escalation choice.

• Oral: Route (tablet, twice daily typical)
• ↓ Hepatic glucose: Mechanism (output reduction)
• ~25–40%: Failure rate (need added insulin)
• High: Convenience (vs injectable)

Why metformin is often tried first

Placeholder: oral convenience and patient preference favor metformin trials.

Insulin Injectable Therapy Option

Insulin remains the historic gold-standard glycemic control option.

• Injectable: Route (subcutaneous)
• No: Placental crossing (large molecule)
• Titratable: Control (dose adjusted per reading)
• Higher: Burden (injections, monitoring)

Why insulin is still favored in some cases

Placeholder: insulin offers precise titration without placental transfer.

Placental Transfer Consideration

Metformin crosses the placenta while insulin largely does not.

• Yes: Metformin crossing (fetal exposure occurs)
• Minimal: Insulin crossing (large peptide molecule)
• Limited: Long-term data (ongoing follow-up studies)
• Recommended: Shared decision (patient counseling)

Weighing fetal exposure against convenience

Placeholder: transfer profile factors into shared treatment decisions.

Combination Therapy If Needed

Metformin and insulin together when monotherapy underperforms.

• ~25–40%: Combo use (of treated GDM cases)
• Additive: Rationale (complementary mechanisms)
• Intensive: Monitoring (frequent glucose checks)
• Target range: Goal (fasting & postprandial)

Escalating to dual therapy

Placeholder: combination used when single-agent targets are not met.

Placeholder: individualized titration guides the final regimen.